Trinity Biotech (TRIB) announced that this week its New York, reference laboratory has received regulatory approval from the New York State Department of Health, NYSDOH, to begin providing the FDA-cleared PreClara Ratio, sFlt-1/PlGF, biomarker test for preeclampsia risk assessment. The service is planned to be rolled out in Q3 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Announces Breakthrough in CGM Technology
- Trinity Biotech announces clinical trial results for redesigned CGM sensor
- Trinity Biotech Launches FDA-cleared Preeclampsia Testing Service
- Trinity Biotech announces launch of FDA-cleared preeclampsia testing service
- Trinity Biotech Launches CGM+ Platform for AI Wearables Market